Biotech · Private company
Bioverativ, a Sanofi company
Track this companyFree. Adds Bioverativ, a Sanofi company to your Dealase workspace and tells you when its record changes.
Clinical trials141 recruiting or active
Pipeline programs18From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline18
- BIVV009Phase 3 · Agglutinin Disease, ColdClinicalTrials.gov · fetched Nov 12, 2026
- efanesoctocog alfa (BIVV001)Phase 3 · Hemophilia AClinicalTrials.gov · fetched Nov 12, 2026
- efanesoctocog alfa (BIVV001)Phase 3 · Factor VIII DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- rFIXFcPhase 3 · Hemophilia BClinicalTrials.gov · fetched Nov 12, 2026
- rFVIIIFcPhase 3 · Hemophilia AClinicalTrials.gov · fetched Nov 12, 2026
- sutimlimab (BIVV009)Phase 3 · Cold Agglutinin DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Advate (High Dose)Phase 2 · Hemophilia AClinicalTrials.gov · fetched Nov 12, 2026
- Advate (Low Dose)Phase 2 · Hemophilia AClinicalTrials.gov · fetched Nov 12, 2026
- BIVV001 (High Dose)Phase 2 · Hemophilia AClinicalTrials.gov · fetched Nov 12, 2026
- BIVV001 (Low Dose)Phase 2 · Hemophilia AClinicalTrials.gov · fetched Nov 12, 2026
- SAR445088 (BIVV020)Phase 2 · Immune Thrombocytopenia (ITP)ClinicalTrials.gov · fetched Nov 12, 2026
- SAR445088 (IV)Phase 2 · Chronic Inflammatory Demyelinating PolyradiculoneuropathyClinicalTrials.gov · fetched Nov 12, 2026
- SAR445088 (SC)Phase 2 · Chronic Inflammatory Demyelinating PolyradiculoneuropathyClinicalTrials.gov · fetched Nov 12, 2026
- BIVV009 6.5 gramsPhase 1 · Purpura, Thrombocytopenic, IdiopathicClinicalTrials.gov · fetched Nov 12, 2026
- BIVV009 7.5 gramsPhase 1 · Purpura, Thrombocytopenic, IdiopathicClinicalTrials.gov · fetched Nov 12, 2026
- BIVV020Phase 1 · Autoimmune Haemolytic AnaemiaClinicalTrials.gov · fetched Nov 12, 2026
- efanesoctocog alfa (BIVV001)Phase 1 · Von Willebrand's Disease (VWD)ClinicalTrials.gov · fetched Nov 12, 2026
- rFVIIIFcHemophilia A With InhibitorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials14
- To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)PHASE1 · COMPLETED · started May 3, 2021ClinicalTrials.gov NCT04770935 · fetched Nov 12, 2026
- Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)PHASE2 · COMPLETED · started Apr 28, 2021ClinicalTrials.gov NCT04658472 · fetched Nov 12, 2026
- Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia APHASE3 · ACTIVE_NOT_RECRUITING · started Feb 23, 2021ClinicalTrials.gov NCT04644575 · fetched Nov 12, 2026
- Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia APHASE3 · COMPLETED · started Feb 19, 2021ClinicalTrials.gov NCT04759131 · fetched Nov 12, 2026
- A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)PHASE2 · COMPLETED · started Feb 4, 2021ClinicalTrials.gov NCT04669600 · fetched Nov 12, 2026
- A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin DiseasePHASE1 · COMPLETED · started Jun 15, 2020ClinicalTrials.gov NCT04269551 · fetched Nov 12, 2026
- A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia APHASE3 · COMPLETED · started Nov 19, 2019ClinicalTrials.gov NCT04161495 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood TransfusionPHASE3 · COMPLETED · started Mar 17, 2018ClinicalTrials.gov NCT03347422 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)PHASE3 · COMPLETED · started Mar 5, 2018ClinicalTrials.gov NCT03347396 · fetched Nov 12, 2026
- A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)PHASE4 · COMPLETED · started Dec 8, 2017ClinicalTrials.gov NCT03093480 · fetched Nov 12, 2026
- A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)PHASE1_PHASE2 · COMPLETED · started Aug 28, 2017ClinicalTrials.gov NCT03205163 · fetched Nov 12, 2026
- A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)PHASE1 · COMPLETED · started Aug 14, 2017ClinicalTrials.gov NCT03275454 · fetched Nov 12, 2026
- An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia APHASE3 · COMPLETED · started Jan 12, 2015ClinicalTrials.gov NCT02234323 · fetched Nov 12, 2026
- Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia BPHASE3 · COMPLETED · started Nov 13, 2014ClinicalTrials.gov NCT02234310 · fetched Nov 12, 2026